Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of chemical raw materials, including intermediates, and pharmaceutical products. The company’s core product portfolio includes active pharmaceutical ingredients (APIs) such as non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen; cardiovascular raw materials torasemide and milrinone; antitumor raw materials including abiraterone acetate and fludarabine phosphate; anticholinergic agent granisetron hydrochloride; as well as pharmaceutical preparations like torasemide tablets and ibuprofen granules. The company also produces chemical products including dimethyl ether gas and a-chloropropionyl chloride and operates contract development and manufacturing services (CDMO) allowing for customized R&D and production based on client requirements. Its products are exported to over 85 countries globally, including regulated markets in the USA and EU.
Founded in 1995 and headquartered in Jingmen, Hubei Province, China, the company operates two API production sites and an R&D center, passing multiple inspections and approvals from the US FDA and EU GMP authorities. Recent developments include the launch of ibuprofen sustained-release capsules, which obtained pharmaceutical registration certification from China’s National Medical Products Administration, representing an expansion in its product formulation offerings. The company maintains strategic positioning in pharmaceuticals, chemicals, and new energy fuel sectors and has seen notable stock performance growth amid ongoing operational challenges reflected in recent financial results. It remains recognized as a high-tech enterprise in Hubei Province and among China’s top 20 CDMO enterprises.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. continues to focus on diversifying its product range within cardiovascular, anti-inflammatory, antitumor, and anti-infective therapeutic categories, serving both domestic and international markets with a comprehensive pipeline of APIs, intermediates, tablets, granules, and capsules alongside contract manufacturing services. Its ongoing regulatory approvals and product innovations underpin its competitive position in the pharmaceutical manufacturing sector.